Stock listing

OTC:LYRA Lyra Therapeutics, Inc. Stock

Follow Lyra Therapeutics, Inc. into a list and get an email when it puts out news.

Share price · OTC:LYRA

$0.03 USD 0.00 (0.0%)

Close on Nov 20, 2026

Past year -99.0% · daily closes, Nov 20, 2025 – Nov 20, 2026, adjusted for splits
Day range
$0.03 – $0.03 USDNov 20, 2026
Volume
434 sharesNov 20, 2026
Market cap
$53,246 USDAt the close on Nov 20, 2026 · price × 1.77M shares outstanding
52-week range
$0.0004 – $4.59 USDLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
Traded on an average day
$118 USDMedian day 110 shares · 31 days with no trades · last 3 months, Aug 20, 2026 – Nov 20, 2026
Lyra Therapeutics, Inc. logo

Daily closes

Last 3 months, Aug 20, 2026 – Nov 20, 2026 · OTC:LYRA · USD, adjusted for splits

DayCloseChange%OpenHighLowVolume
$0.030.000.0%$0.03$0.03$0.03434
$0.030.000.0%$0.03$0.03$0.03206
$0.030.000.0%$0.03$0.03$0.03241
$0.030.000.0%$0.03$0.03$0.03266
$0.03-0.16-84.2%$0.03$0.03$0.038,139
$0.190.000.0%$0.19$0.19$0.190
$0.190.000.0%$0.0004$0.195$0.00041,372
$0.190.000.0%$0.19$0.19$0.190
$0.190.000.0%$0.19$0.19$0.190
$0.190.000.0%$0.19$0.19$0.190
$0.190.000.0%$0.19$0.19$0.190
$0.190.000.0%$0.03$0.19$0.03401
$0.190.000.0%$0.19$0.19$0.190
$0.190.000.0%$0.19$0.19$0.190
$0.190.000.0%$0.03$0.19$0.03403
$0.190.000.0%$0.19$0.19$0.190
$0.190.000.0%$0.19$0.19$0.190
$0.190.000.0%$0.19$0.19$0.190
$0.190.000.0%$0.03$0.19$0.0310,110
$0.190.000.0%$0.19$0.19$0.190
$0.190.000.0%$0.19$0.19$0.190
$0.190.000.0%$0.19$0.19$0.190
$0.190.000.0%$0.19$0.19$0.190
$0.190.000.0%$0.19$0.19$0.190
$0.190.000.0%$0.03$0.19$0.034,321
$0.190.000.0%$0.19$0.19$0.190
$0.190.000.0%$0.19$0.19$0.190
$0.190.000.0%$0.19$0.19$0.190
$0.190.000.0%$0.051$0.19$0.051420
$0.190.000.0%$0.0005$0.195$0.00051,637
$0.19-0.005-2.6%$0.03$0.19$0.032,100
$0.195+0.005+2.6%$0.03$0.195$0.032,102
$0.190.000.0%$0.19$0.19$0.190
$0.190.000.0%$0.19$0.19$0.190
$0.19+0.04+26.7%$0.145$0.19$0.142317
$0.150.000.0%$0.15$0.15$0.15348
$0.15-0.05-25.0%$0.03$0.15$0.032,678
$0.200.000.0%$0.20$0.20$0.200
$0.200.000.0%$0.20$0.20$0.200
$0.200.000.0%$0.20$0.20$0.20213
$0.200.000.0%$0.20$0.20$0.200
$0.200.000.0%$0.051$0.20$0.051600
$0.200.000.0%$0.051$0.20$0.0511,118
$0.200.000.0%$0.20$0.20$0.200
$0.200.000.0%$0.20$0.20$0.200
$0.200.000.0%$0.03$0.20$0.032,206
$0.200.000.0%$0.20$0.20$0.200
$0.200.000.0%$0.20$0.20$0.200
$0.200.000.0%$0.20$0.20$0.200
$0.200.000.0%$0.20$0.20$0.200
$0.20+0.01+5.3%$0.20$0.20$0.20110
$0.19-0.01-5.0%$0.03$0.19$0.03224
$0.200.000.0%$0.45$0.52$0.205,469
$0.200.000.0%$0.20$0.20$0.200
$0.200.000.0%$0.20$0.20$0.200
$0.200.000.0%$0.01$0.20$0.01456
$0.20+0.19+1900.0%$0.155$0.205$0.01881
$0.010.000.0%$0.01$0.01$0.011,011
$0.010.000.0%$0.01$0.01$0.01406
$0.010.000.0%$0.01$0.01$0.011,046
$0.010.000.0%$0.01$0.01$0.01119
$0.01+0.01+2400.0%$0.01$0.01$0.01425
$0.00040.000.0%$0.0004$0.0004$0.0004815

Splits

1 split · OTC:LYRA · every price before a split is adjusted for it

DayRatioWhat
1-for-50Consolidation
Ticker
OTC:LYRA
Asset type
Stock
Sector
Health care
Industry
Biotechnology
Exchange
OTC
Currency
USD

Lyra Therapeutics, Inc. on 6ix

Sector
Health care
Industry
Biotechnology
Calls
4 calls with a replay · 4 with a transcript · latest Nov 9, 2021
Decks
14 decks · latest September 2025

Valuation

EV/sales 36.2× against a median of 0.7×: 3rd lowest of 4 Biotechnology companies shown. Statements: Year to Dec 31, 2025 · price Nov 20, 2026

Enterprise value
$14.42M USD
P/E
Loss
EV/sales
36.2×
EV/EBITDA
Negative EBITDA
Price/book
Negative equity
Gross margin
100.0%
Operating margin
Revenue too small
Net margin
Revenue too small
Debt to equity
Negative equity
Beta vs S&P 500
0.67

Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.

CompanyMkt capEVP/EEV/SalesEV/EBITDAP/BNet mgnDebt/EqBeta
Lyra Therapeutics, Inc. · OTC:LYRAUS$53,246US$14.42Mn/a36.2×n/an/an/an/a0.67
NKGen Biotech Inc. · OTC:NKGNUS$391,807US$38.58Mn/an/an/an/an/an/a0.88
Vaxil Bio Ltd. · TSXV:VXLUS$319,500−US$4,0701.2×n/an/a0.4×n/a0.0×-0.16
Chimeric Therapeutics Limited · ASX:CHMUS$292,816−US$220,193n/a−0.1×n/a0.2×−262.8%2.5×n/a
CERo Therapeutics Holdings, Inc. · OTC:CEROUS$265,035−US$190,890n/an/an/an/an/an/a1.47
CDT Equity Inc. · NASDAQ:CDTUS$234,109−US$1.49Mn/an/an/a0.0×n/a0.0×1.14
GlucoTrack, Inc. · NASDAQ:GCTKUS$217,049−US$887,951n/an/an/an/an/an/a1.73
Regen BioPharma, Inc. · OTC:RGBPUS$167,528US$167,289n/a0.7×n/an/a−501.4%n/a1.20
CNBX Pharmaceuticals Inc. · OTC:CNBXUS$160,577US$151,090n/an/an/an/an/an/a1.78
Fifty 1 Labs Inc. · OTC:FITYUS$118,532US$282,021n/a6,000×n/an/an/an/a-1.17
GB Sciences, Inc. · OTC:GBLXUS$81,414US$2.07Mn/an/an/an/an/an/a-0.46
Median of the othersUS$225,579US$73,5101.2×0.7×0.2×−382.1%0.0×1.14

Forecasts

4 hold · Analysts' consensus from EODHD, read Nov 18, 2026. Not 6ix's view and not investment advice.

Price target
16.00 USD · Analysts' mean
EPS, year to Dec 2025
-25.66 · 1 analyst

Team and board

Officers

OfficerRole
Maria PalasisPresident and Chief Executive Officer

Board

DirectorRole
Bradford SmithBoard Director
George WhitesidesWoodford L. and Ann A. Flowers University Professor, Harvard University
Jim TobinLead Independent Director
Maria PalasisPresident and Chief Executive Officer
Nancy L. SnydermanBoard Director
Robert LangerDavid H. Koch Institute Professor, Massachusetts Institute of Technology

Events

Calls

CallWhenStatus
Lyra Therapeutics (OTC:LYRA) Q3 2021 Earnings CallTue, Nov 09, 2021 · 4:30 PM ETReplay
Lyra Therapeutics (OTC:LYRA) Q2 2021 Earnings CallMon, Aug 09, 2021 · 4:30 PM ETReplay
Lyra Therapeutics (OTC:LYRA) Q1 2021 Earnings CallTue, May 11, 2021 · 4:30 PM ETReplay
Lyra Therapeutics (OTC:LYRA) Q4 2020 Earnings CallTue, Mar 09, 2021 · 4:30 PM ETReplay

Results days

QuarterResultsShare move
Q3 2025Nov 12, 2025 · After close−1.6%
Q2 2025Aug 12, 2025 · After close+8.0%
Q1 2025May 6, 2025 · After close+2.9%
Q4 2024Mar 19, 2025 · Before open−0.6%
Q3 2024Nov 12, 2024 · After close−28.0%
Q2 2024Aug 14, 2024 · After close+1.1%
Q1 2024Apr 30, 2024 · After close+1.7%
Q4 2023Mar 21, 2024 · After close+2.8%
Q3 2023Nov 7, 2023 · After close0.0%
Q2 2023Aug 8, 2023 · After close+2.2%
All 20 quarters
QuarterResultsShare move
Q1 2023May 12, 2023 · Before open−4.6%
Q4 2022Mar 29, 2023 · After close+2.5%
Q3 2022Nov 8, 2022 · After close−15.5%
Q2 2022Aug 9, 2022 · Before open−4.1%
Q1 2022May 10, 2022 · Before open+6.6%
Q4 2021Mar 9, 2022 · Before open−5.3%
Q3 2021Nov 9, 2021 · After close+2.8%
Q2 2021Aug 9, 2021 · After close+0.1%
Q1 2021May 11, 2021 · After close−1.7%
Quarter to Dec 31, 2020Mar 9, 2021 · After close−6.8%

Open Events

Decks

DeckKindSlidesDate
Investor Presentation (September 2025)Investor deck20 slidesSeptember 2025
Investor Presentation (August 2025)Investor deck21 slidesAug 12, 2025
Investor Presentation (June 2025)Investor deck26 slidesJun 9, 2025
Technical Presentation (June 2025)Technical17 slidesJun 2, 2025
Investor Presentation (June 2025)Investor deck25 slidesJun 2, 2025
Investor Presentation (January 2025)Investor deck22 slidesJan 10, 2025
Technical Presentation (2025)Technical17 slides2025
Investor Presentation (August 2024)Investor deck25 slidesAug 14, 2024
Investor Presentation (January 2024)Investor deck23 slidesJan 8, 2024
69th Annual Meeting of the American Rhinologic Society (ARS) 2023Conference12 slidesSep 30, 2023
All 14 decks
DeckKindSlidesDate
Technical Presentation (September 2023)Technical13 slidesSep 12, 2023
Investor Presentation (March 2023)Investor deck20 slidesMar 29, 2023
Technical Presentation (September 2022)Technical21 slidesSep 12, 2022
Combined Otolaryngology Spring Meetings (COSM) 2021Conference15 slidesApr 13, 2021

Open Decks

Financials

Annual, in USD

Income statement

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018
Revenue398.0K1.53M1.56M1.36M285.0K001.24M
Cost of revenue471.0K48.0M1.07M1.00M12.5M27.0K
Gross profit398.0K1.53M1.56M1.36M285.0K-12.5M-27.0K1.24M
Research and development18.4M43.8M48.0M38.8M29.7M12.5M12.0M4.97M
Selling, general and administrative11.5M18.5M19.1M17.6M14.2M9.69M4.49M3.53M
Operating income-31.0M-96.3M-67.1M-56.3M-43.6M-22.2M-16.5M-7.26M
Depreciation and amortization459.0K471.0K278.0K1.07M1.00M95.0K27.0K82.0K
EBITDA-30.6M-95.9M-66.8M-55.2M-42.6M-22.1M-16.5M-7.18M
Interest expense524.0K102.0K82.0K213.0K1.23M
Income before tax-28.9M-93.4M-62.6M-55.3M-43.5M-22.1M-16.3M-6.03M
Income tax11.0K39.0K59.0K13.0K-1.10M-82.0K-213.0K-1.23M
Net income-28.9M-93.4M-62.7M-55.3M-42.4M-22.1M-16.3M-6.03M
Earnings per share, basic-1.86-1.43-1.26-1.83-3.27-2.58-1.99-0.96

Balance sheet

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018
Cash and equivalents15.9M40.6M22.4M32.5M45.7M74.6M9.81M23.9M
Short-term investments080.4M65.3M0
Receivables167.0K
Inventory1
Current assets16.3M43.0M104.8M100.8M47.9M75.9M10.1M24.9M
Property, plant and equipment4.47M5.86M2.17M3.42M103.0K
Total assets36.1M66.3M142.6M110.0M54.9M80.8M15.0M25.4M
Accounts payable663.0K1.18M3.13M2.62M3.13M922.0K1.07M631.0K
Current liabilities9.52M12.6M19.6M14.5M18.2M4.88M5.21M1.96M
Total debt30.3M34.4M26.9M4.18M1.45M2.44M3.33M
Total liabilities46.8M54.8M53.2M29.2M20.6M6.34M7.63M132.4M
Shareholders' equity-10.7M11.6M89.4M80.8M34.3M74.5M7.33M-107.1M
Shares outstanding15.5M65.1M49.8M30.2M13.0M8.59M8.18M6.27M

Cash flow

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018
Cash from operations-28.9M-70.0M-63.3M-43.4M-25.8M-21.1M-13.8M-6.64M
Capital spending-116.0K-2.34M-1.05M-164.0K-3.38M-1.77M-211.0K-37.0K
Free cash flow-29.0M-72.3M-64.4M-43.5M-29.2M-22.9M-14.0M-6.68M
Cash from investing-98.0K80.3M-12.6M-65.0M-3.38M-1.77M-211.0K-37.0K
Cash from financing4.27M8.53M65.7M96.3M359.0K87.7M-115.0K29.2M
Share buybacks57.5M111.0K29.0M
Change in cash-24.7M18.8M-10.2M-12.1M-28.8M64.8M-14.1M22.5M

Open Financials

Cap table

Built by 6ix from Lyra Therapeutics, Inc.’s releases

Common shares
1,774,882
Fully diluted
1,774,882

Fully diluted

LineShares
Common shares1,774,882

Share count over time

CountShares
Nov 22, 20261,774,882

Open Cap table

People

6ix reads each seat by machine from the page it links to, and can misread one.

PersonSeat
Robert Langer
Other companies: Seer, Inc. (Director · Since at least Dec 3, 2020); Korro Bio, Inc. (Director · Oct 2, 2019 – Aug 17, 2022 · Past); Moderna, Inc. (Director · Dec 7, 2018 – May 6, 2024 · Past); Rubius Therapeutics Inc (Director · Jul 17, 2018 – Oct 14, 2019 · Past); Kala Bio, Inc. (Director · Jul 19, 2017 – Jun 12, 2018 · Past); BIND Therapeutics Inc (Director · Sep 19, 2013 – Jun 21, 2016 · Past); Ocata Therapeutics Inc (Director · Oct 4, 2011 – Feb 10, 2016 · Past)
David H. Koch Institute Professor, Massachusetts Institute of Technology · Since at least Apr 30, 2020
Don Elsey
Other companies: BullFrog AI Holdings, Inc. (Director · Since at least Feb 13, 2023); RegeneRx Biopharmaceuticals, Inc. (Member of our Board of Directors · Since at least Sep 1, 2017); CapForce Inc. (Director · Feb 21, 2019 – Jun 7, 2023 · Past); Senseonics Holdings, Inc. (CFO, Secretary and Treasurer · Apr 12, 2016 – Feb 2, 2018 · Past)
CFO, Treasurer & Secretary · Apr 30, 2020 – Feb 8, 2021 · Past
C Ann Merrifield
Other companies: Juniper Pharmaceuticals Inc (Director · Jul 16, 2015 – Aug 14, 2018 · Past); InVivo Therapeutics Holdings Corp (Director · Nov 8, 2014 – Nov 17, 2022 · Past); Flexion Therapeutics Inc (Director · Jun 11, 2014 – Nov 19, 2021 · Past)
Director · Apr 30, 2020 – May 14, 2025 · Past
James R. Tobin
Other companies: TransMedics Group, Inc. (Director · Since at least Feb 9, 2021); Globus Medical, Inc. (Director · Since at least Jan 14, 2021); Oxford Immunotec Global PLC (Director · Mar 8, 2021 – Mar 8, 2021 · Past)
Lead Independent Director · Since at least Mar 4, 2022
John Bishop
Other companies: Ardelyx, Inc. (Chief Technical and Quality Officer · Since at least Aug 1, 2025); Forma Therapeutics Holdings Inc (SVP, Chief Technology Officer · Jun 14, 2021 – Oct 14, 2022 · Past); Momenta Pharmaceuticals Inc (Senior VP, Pharmaceutical Scie · Feb 17, 2006 – May 19, 2016 · Past)
Chief Technology Officer · Feb 27, 2023 – Jan 30, 2024 · Past
Michael Seth Altman
Other companies: ARYA Sciences Acquisition IV Corp (Chief Financial Officer, Director · Jul 31, 2024 – Jul 31, 2024 · Past); Freenome, Inc. (Chief Business Officer, Director · Jun 11, 2024 – Jun 13, 2024 · Past); Nautilus Biotechnology, Inc. (Director · Jun 15, 2022 – Jun 14, 2024 · Past)
Director · Jun 16, 2022 – Jun 13, 2024 · Past
Nancy L. Snyderman
Other companies: Alkermes plc (Director · Since at least May 23, 2018); Future Health Esg Corp (Director · Sep 9, 2021 – Oct 24, 2021 · Past); Axonics Modulation Technologies Inc (Director · Apr 8, 2019 – Aug 24, 2020 · Past)
Board Director · Since at least Oct 27, 2020
Maria Palasis
Other companies: Beta Bionics, Inc. (Board Member · Since at least Jan 29, 2025)
President and Chief Executive Officer · Since at least Apr 30, 2020
Bradford SmithBoard Director · Since at least Nov 5, 2026
Corinne NoyesSee Remarks · Apr 30, 2020 – Jan 31, 2023 · Past
All 14 people
PersonSeat
George WhitesidesWoodford L. and Ann A. Flowers University Professor, Harvard University · Since at least Nov 5, 2026
Jason CavalierPrincipal Financial Officer · Since at least Sep 13, 2021
Pamela E NelsonSVP, Regulatory Affairs · Aug 3, 2020 – Feb 12, 2022 · Past
Robert E RichardSVP, Technical Operations · Jun 24, 2020 – Jan 31, 2023 · Past

Open People

Log in to ask 6ix AI your own questions about Lyra Therapeutics, Inc.